Markets

  • Evommune Announces IPO Pricing

    Evommune, Inc. announced the pricing of its IPO of 9,375,000 shares at $16.00 per share, expected to begin trading on the NYSE (EVMN) on November 6, 2025. The offering is anticipated to close on November 7, 2025, and includes an underwriter option for additional shares. Gross proceeds are projected at $150 million. Morgan Stanley, Leerink Partners, Evercore ISI, and Cantor are joint book-runners. Evommune will use the funds to advance its pipeline of therapies targeting chronic inflammatory diseases.

    2025年11月21日
  • NewLake Capital Partners Announces Q3 2025 Earnings

    NewLake Capital Partners (NLCP) reported its Q3 2025 financial results with revenue of $12.6 million, a slight YoY increase. Net income attributable to common stockholders was $6.7 million, FFO totaled $10.7 million, and AFFO reached $11.0 million. NLCP declared a dividend of $0.43 per share. The company focused on tenant management amidst industry headwinds. A conference call is scheduled for November 6, 2025, to discuss the results. NLCP is a REIT specializing in the cannabis industry.

    2025年11月21日
  • PG&E Offers Free Gas Appliance Safety Checks and Pilot Light Relights As Temperatures Drop, Addressing Carbon Monoxide Risks

    PG&E is offering free in-home gas safety checks to its 16 million customers across Northern and Central California to prevent carbon monoxide (CO) poisoning during the winter heating season. The checks include inspecting appliances like water heaters and furnaces and re-lighting pilot lights. CO poisoning causes over 400 U.S. deaths annually. PG&E advises installing CO and methane detectors, ensuring proper ventilation, and never using outdoor appliances indoors. Suspected CO poisoning or gas leaks require immediate evacuation and calls to 911 and PG&E.

    2025年11月21日
  • ConnectM Acquires Geo Impex for AI Data Center and Logistics Hub Development

    ConnectM Technology Solutions acquired Geo Impex & Logistics, gaining control of 76 acres near key transportation hubs in Odisha, India. This strategic location, approved for industrial development, will host a multimodal logistics park and an AI-enabled Energy Intelligence Data Center (EIDC). ConnectM aims to integrate its AI energy technology, including Amperics battery technology and Keen Labs’ software, to create a sustainable platform optimizing logistics, power, and data convergence. CEO Bhaskar Panigrahi sees this as a blueprint for sustainable industrial growth.

    2025年11月21日
  • VPG to Hold Investor Meetings at Southwest IDEAS Conference in Dallas

    Vishay Precision Group (VPG), a leader in precision measurement and sensing technologies, will present at the 17th Annual Southwest IDEAS Investor Conference on November 20, 2025, in Dallas, TX. A live webcast of VPG’s presentation, scheduled for 7:55 a.m. CT, will be available. The conference provides a platform for VPG to showcase its investment potential and elaborate on growth strategies and technological innovations. VPG’s solutions serve industries like aerospace and medical, where demand is robust.

    2025年11月21日
  • T-Mobile Extends Text to 911 Off-Grid to All Wireless Users, Including Verizon and AT&T Customers

    T-Mobile is expanding its satellite-based Text to 911 service, powered by T-Satellite and Starlink, to all compatible wireless devices, regardless of carrier. This provides a crucial safety net in 500,000 square miles of the U.S. lacking traditional cell coverage. While competitors offer device-specific solutions, T-Mobile offers free access to Text to 911 for all users meeting the specified criteria. They also have options with more functionality and is raising important questions about upgrades for emergency response infrastructure.

    2025年11月21日
  • VIQ Solutions Completes Oversubscribed Private Placement

    VIQ Solutions (VQSSF) closed the second tranche of an upsized private placement on November 5, 2025, raising approximately C$585,000. The company issued 3,146,063 units at C$0.186 per unit, each including a share and a warrant exercisable at C$0.190 until 2030. Total proceeds from the placement exceed C$3.0 million. Proceeds will fund technology innovations, organic growth, acquisitions, and restructuring. The issuance of new units will cause some share dilution.

    2025年11月21日
  • Ares Management Finalizes Investment in Plenitude

    Ares Management Corporation has acquired a 20% stake in Plenitude, Eni’s energy transition business, for €2 billion, valuing Plenitude at over €12 billion. The investment highlights the growing interest in energy transition companies like Plenitude, which integrates renewable energy generation, energy sales, and EV charging infrastructure across 15 countries. Plenitude aims to reach 10 GW of renewable capacity by 2028. Ares’ investment aligns with its strategy of deploying capital in sectors driven by long-term secular trends, particularly the energy transition.

    2025年11月21日
  • E3 Lithium Webinar: November 5, 2025, 9:00 AM MT

    E3 Lithium will host a webinar on November 5, 2025, at 9:00 AM MT, led by CEO Chris Doornbos. Updates will cover progress on Phase 1 & 2 Demonstration Facilities, recent equity financing, and E3 Lithium’s role in the North American critical minerals landscape. Governmental initiatives and upcoming milestones for the Clearwater Project in Q4 2025 and 2026 will also be discussed. A live Q&A session will follow a 45-minute presentation, with a recording available on the company’s website. E3 Lithium focuses on developing lithium resources in Alberta and Saskatchewan, emphasizing Direct Lithium Extraction technologies.

    2025年11月21日
  • Innate Pharma to Host Q3 2025 Results and Business Update Conference Call & Webcast

    Innate Pharma SA (IPHA) will host a conference call on November 13, 2025, to discuss its Q3 2025 business progress. Key executives will present and answer questions. The call will be webcast live and available for replay on the company website. Innate Pharma focuses on developing immunotherapies, including lacutamab, IPH4502, and monalizumab. Investors will focus on clinical trial updates, cash runway, and competitive advantages. Note the presence of forward-looking statements subject to risks detailed in company filings.

    2025年11月21日